Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran

Conclusion:
Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.

Source: Journal of Pharmacy Practice - November 15, 2015 Category: Drugs & Pharmacology Authors: Miyares, M. A., Kuyumjian, Y., Eaves, S., Dollard, E. Tags: Review Articles Source Type: research